Stocks and Investing
Stocks and Investing
Tue, September 17, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, September 16, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Douglas Tsao Reiterated (TBPH) at Strong Buy and Held Target at $15 on, Sep 16th, 2024
Douglas Tsao of HC Wainwright & Co., Reiterated "Theravance Biopharma, Inc." (TBPH) at Strong Buy and Held Target at $15 on, Sep 16th, 2024.
Douglas has made no other calls on TBPH in the last 4 months.
There are 2 other peers that have a rating on TBPH. Out of the 2 peers that are also analyzing TBPH, all agree with Douglas's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- David Risinger of "Leerink Partners" Downgraded from Buy to Hold and Decreased Target to $10 on, Tuesday, August 6th, 2024
- Marc Frahm of "TD Cowen" Maintained at Hold with Decreased Target to $9 on, Tuesday, August 6th, 2024
Contributing Sources